ClinicalTrials.gg

Program

palacaparib

Also written as “Palacaparib (AZD9574)”, “AZD8205 in combination with AZD9574” and “AZD9574”.

Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Oct 13, 20213 company-led studies, 3 open or runningNext primary completion: Sep 29, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca33 open or runningphase 2since Oct 13, 2021Oct 13, 2021Sep 29, 2027phase 2 · NCT05123482
  • Named in AstraZeneca’s own pipeline as AZD9574, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2021First study: phase 2 study in Breast NeoplasmsFirst studyNCT05123482 · 460 planned · United States, Australia, Belgium and more
  2. May 20, 2022Phase 2 study in Breast NeoplasmsNCT05417594 · 695 planned · United States, Australia, Germany and more
  3. May 11, 2026Phase 2 study in Prostatic NeoplasmsNCT07590934 · 152 planned · United States, Australia, Germany and more

Ahead

  1. Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
  2. Feb 7, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT05417594
  3. Sep 25, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07590934

TargetBeta

“An orally bioavailable central nervous system (CNS) penetrant and inhibitor of nuclear enzyme poly(ADP-ribose) polymerase (PARP) 1, with potential antineoplastic activity. Upon oral administration, palacaparib selectively binds to PARP1, thereby preventing repair of damaged DNA via the base excis…”NCIt, read by Claude

Other programs on PARP1

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
saruparibruleAstraZenecaphase 314
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24
PARP1 Inhibitor HS-10502ruleHansoh Pharmaceutical Groupphase 12
DM5167ruledigmbiophase 11
HSK46256ruleHaisco Pharmaceutical Groupphase 11
TQB3122Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07590934Prostatic Neoplasms · United States, Australia, Germany and more2RecruitingSep 25, 2029152
NCT05417594Breast Neoplasms · United States, Australia, Germany and more2RecruitingFeb 7, 2028695
NCT05123482Breast Neoplasms · United States, Australia, Belgium and more2RecruitingSep 29, 2027460

How it is read

Names in the registry

  • “Palacaparib (AZD9574)”, 1 entry
  • “AZD8205 in combination with AZD9574”, 1 entry
  • “AZD9574”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.